Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
30 participants
Aug 1, 2021
OBSERVATIONAL
Conditions
Summary
As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.
Eligibility
Inclusion Criteria6
- no drug contraindications .
- aged between 45 and 75 .
- committed to follow the research procedures, And cooperate with the •implementation of the whole process study .
- the patient understands the relevant treatment process .
- the patient has the ability to give informed consent .
- The patient had not recently taken any medication that affected observation.
Exclusion Criteria6
- mental illness .
- patients with malignant tumors.
- patients with other infectious diseases .
- patients with metabolic bone disease, diabetes and hyperthyroidism.
- patients who cannot actively cooperate in the treatment.
- hypocalcemia.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Desumumab, 60mg single injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06357741